The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 29, 2016
Filed:
Apr. 14, 2010
Yoon Sup Choi, Busan, KR;
Jun Ho Chung, Seoul, KR;
Ji Ho Yoo, Seoul, KR;
Hyun Soo Cho, Gyeonggi, KR;
Su Min Yoon, Seoul, KR;
Kyung Lock Kim, Busan, KR;
Sung Ho Ryu, Gyeongbuk, KR;
Sang Uk Kim, Gyeongbuk, KR;
Yoon Sup Choi, Busan, KR;
Jun Ho Chung, Seoul, KR;
Ji Ho Yoo, Seoul, KR;
Hyun Soo Cho, Gyeonggi, KR;
Su Min Yoon, Seoul, KR;
Kyung Lock Kim, Busan, KR;
Sung Ho Ryu, Gyeongbuk, KR;
Sang Uk Kim, Gyeongbuk, KR;
POSTECH ACADEMY-INDUSTRY FOUNDATION, Gyeongbuk, KR;
Abstract
The present invention relates to a method for preparing a target-specific non-antibody protein, and more particularly, to a method for preparing a target-specific non-antibody protein comprising the steps of: selecting non-antibody proteins having a structural complementarity with the target site of a target protein in a non-antibody protein library; calculating a binding energy of the selected non-antibody protein and the target protein; selecting a non-antibody protein having a favorable binding energy among the selected non-antibody proteins; selecting amino acid residues having a high binding energy among the interfacial amino acid residues of the selected non-antibody protein and the target protein; and substituting the selected amino acid residues with the amino acid residues having a low binding energy. In addition, the present invention relates to a target-specific non-antibody specifically binding with EGFR (Epidermal Growth Factor Receptor) domain 2, which is prepared by the method, and a cancer therapeutic composition comprising the same.